Cytomegalovirus UL44 Protein as a new target of Humoral Immune Response in Solid Organ Transplant Recipients
Ontology highlight
ABSTRACT: Due to the severity of CMV infection and the high number of deaths associated to this pathogen, the American Institute of Medicine proposed the development of a vaccine as a priority. Numerous attempts have been made to develop vaccines against CMV however, the complex interaction between CMV and the immune system and the absence of an animal model able to reproduce human physiology associated to CMV infection have hindered the development of a vaccine. Based on the long history of unsuccessful trials, it is necessary to keep looking for new CMV antigens that can contribute to induce a wide immune response. We designed a proteomic approach to find, select and characterize CMV antigens that induce a CMV-specific immune response, using serum samples from patients that have developed a protective CMV-specific response after transplantation. Serum samples from 28 kidney transplant recipients that exhibit a high neutralizing antibody response and CMV-specific immune response collected at the University Hospital 12 Octubre in Spain were tested. One sample was collected at transplantation with no or low antibody titers (baseline) and the second sample (post-immunization) after acquiring high neutralizing antibody titers (>1/640). Using serum samples from immunized patients as primary antibody, we detected by western blot CMV antigens that were specifically recognized by the post-immunization serum compared with the baseline serum. Excised proteins were further characterized and identified using liquid chromatography coupled with tandem mass spectrometry. To prove the recognition of the identified protein, the open reading frames were cloned and individually expressed in HEK 293T cells and further detected by western blot using serum samples. To characterize the in vivo immune response elicited against UL44, groups of mice were immunized using the pcDNA-UL44 construct and PBS control. We identified and validated three proteins (UL83, UL55 and UL44). Proteins UL83 (pp65) and UL55 (gB) have previously shown to elicit a potent antibody response, while UL44 was newly identified to elicit a neutralizing antibody immune response. In conclusion, we demonstrate that using serum of immunized patients is an excellent strategy to identify CMV proteins that may be involved on stimulating a wide and protective CMV-specific immunity.
INSTRUMENT(S):
ORGANISM(S): Homo Sapiens (human) Cytomegalovirus Sp.
TISSUE(S): Blood Serum
DISEASE(S): Viral Infectious Disease
SUBMITTER:
Luz Valero
LAB HEAD: Pilar Pérez-Romero
PROVIDER: PXD028655 | Pride | 2026-04-14
REPOSITORIES: Pride
ACCESS DATA